Regulatory barriers mean that Australian women with breast cancer must pay $5000 to access ‘chemo sparing’ tumour profiling tests that are reimbursed as standard of care in other countries, a Parliamentary inquiry has been told. While tests such as Oncotype DX and MammaPrint are recommended and subsidised in many other developed countries, they have been ...
Impasse over ‘chemo sparing’ tumour profiling tests for early breast cancer
By Michael Woodhead
11 May 2021